Haleon plc:
Transaction in
own shares
11
September 2024: Haleon plc (the
"Company" or "Haleon") today announces the
purchase of the following number of ordinary shares of £0.01 each
in the Company (the "Shares") for cancellation under its share buyback programme announced on 1 August
2024 (the "Buyback
Programme").
|
Date of purchase:
|
11 September 2024
|
|
Number of Shares
purchased:
|
506,000
|
|
Highest price paid per Share
(p):
|
396.6000
|
|
Lowest price paid per Share
(p):
|
393.3000
|
|
Volume weighted average price paid
per Share (p):
|
395.0303
|
Following the settlement of the
above, the Company's registered share capital consists of
9,120,364,772 ordinary shares. This figure may be used by
shareholders to determine if they are required to notify their
interest, or a change to their interest, in Haleon under the FCA's
Disclosure Guidance and Transparency Rules.
In accordance with Article 5s(1)(b)
of Regulation (EU) No 596/2014 as it applies in
the UK (the Market Abuse Regulation), a full breakdown of
the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/8383D_1-2024-9-11.pdf
This announcement does not
constitute, or form part of, an offer or any solicitation of an
offer for securities in any jurisdiction.
This announcement and individual
trade breakdown will also be available on the Company's website
at: www.haleon.com/investors.
About Haleon
Haleon (LSE / NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.